The real impact of checkpoint inhibitors is not as hoped - Cancerworld
▻https://cancerworld.net/news/the-real-impact-of-checkpoint-inhibitors-is-not-as-hoped
Cette famille de médicaments n’est efficace que dans 13% des cas chez qui elle est indiquée.
It seems that the big revolution linked to the introduction of checkpoint inhibitor drugs is still far to come. According to estimates recently published in JAMA Network Open, only a small percentage of patients eligible for these treatments respond to them, at odds with great – and probably unrealistic – expectations generated about this way of treating cancer. “If FDA-approved checkpoint inhibitor drugs are universally available, we estimated that the proportion of US patients with cancer who could be eligible for such drugs is approximately 44%, while approximately 13% have a response to these drugs” Alyson Haslam and Vinay Prasad, Oregon Health & Science University, wrote.